Evidence map›Paper›PMID 40920867›Full record

Trial reportPLoS pathogens2025

Cytotoxic CX3CR1+ Vδ1 T cells clonally expand in an interplay of CMV, microbiota, and HIV-1 persistence in people on antiretroviral therapy.

Nived Collercandy, Camille Vellas, Manon Nayrac, Mary Requena, Thomas Richarme, Anne-Laure Iscache, Justine Latour, Karl Barange, Laurent Alric, Guillaume Martin-Blondel and 3 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02906137 (Altered Homing of T Lymphocytes to the Gut and Poor Immune Reconstitution of the Intestinal Mucosa in Treated HIV-infected Individuals), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02906137 nacompletednot on this map

Altered Homing of T Lymphocytes to the Gut and Poor Immune Reconstitution of the Intestinal Mucosa in Treated HIV-infected Individuals

TypeinterventionalSponsorANRS, Emerging Infectious DiseasesRan2017 to 2020Enrolled80ConditionsHIV-1 InfectionArmsPeripheral blood and intestinal biopsies will be collected
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Nived CollercandyINSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Camille VellasINSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Manon NayracINSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Mary RequenaINSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Thomas RicharmeINSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Anne-Laure IscacheINSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Justine LatourCHU de Toulouse, Laboratoire de Virologie, Toulouse, France.
Karl BarangeCHU de Toulouse, Service d'Hépato-Gastro-Entérologie, Toulouse, France.
Laurent AlricCHU de Toulouse, Service de Médecine Interne et Immunologie clinique, Toulouse, France.
Guillaume Martin-BlondelINSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Matteo SerinoInstitut de Recherche en Santé Digestive, INSERM UMR 1220, INRAe, ENVT, Université de Toulouse, Toulouse, France.
Jacques IzopetINSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.
Pierre DelobelINSERM UMR 1291, CNRS UMR 5051, Université de Toulouse, Toulouse Institute for Infectious and Inflammatory Diseases, Toulouse, France.ORCID 0000-0002-2874-3581

Funding

French National Agency for Research on HIV/AIDS and Emerging Infectious Diseases
6 · The paper itself

Abstract

Vδ1 γδ T cells are key players in innate and adaptive immunity, particularly at mucosal interfaces such as the gut. An increase in circulating Vδ1 cells has long been observed in people with HIV-1, but remains poorly understood. We performed a comprehensive characterization of Vδ1 T cells in blood and duodenal intra-epithelial lymphocytes, obtained from endoscopic mucosal biopsies of 15 people with HIV-1 on antiretroviral therapy and 15 HIV-seronegative controls, in a substudy of the ANRS EP61 GALT study (NCT02906137). We deciphered the phenotype, functional profile, single-cell transcriptome and repertoire of Vδ1 cells and unraveled their relationships with the possible triggers involved, in particular CMV and microbiota. We also assessed whether Vδ1 T cells may play a role in controlling the HIV-1 reservoir. Vδ1 T cells were mainly terminally differentiated effectors that clonally expanded in the blood with some trafficking with the gut of people with HIV-1. Most expressed CX3CR1 and displayed a highly cytotoxic profile, but low cytokine production, supported by a transcriptomic shift towards enhanced effector lymphocytes. This expansion was associated with CMV status and markers of occult replication, but also with changes in the duodenal and blood-translocated microbiota. Cytotoxic, but not IFN-γ-producing, Vδ1 T cells were negatively associated with cell-associated HIV-1 RNA in both the blood and duodenal compartments. The increase in Vδ1 T cells observed in people with HIV-1 has multiple triggers, particularly CMV and microbiota, and may in turn contribute to the control of the HIV-1 reservoir.

Indexed as

CX3C Chemokine Receptor 1CytomegalovirusCytomegalovirus InfectionsHIV-1HIV InfectionsAdultAnti-Retroviral AgentsFemaleGastrointestinal MicrobiomeHumansMaleMiddle AgedReceptors, Antigen, T-Cell, gamma-deltaAnti-Retroviral AgentsCX3C Chemokine Receptor 1CX3CR1 protein, humanReceptors, Antigen, T-Cell, gamma-delta

Identifiers

PMID40920867
PMCPMC12431655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.